Amrize Ltd carries a market capitalization of 29.76B, placing it among publicly traded companies globally. Its enterprise value stands at 36.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.76B |
| Enterprise Value | 36.98B |
Amrize Ltd currently has 553.52M shares outstanding.
| Shares Outstanding | 553.52M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Amrize Ltd trades at a trailing price-to-earnings ratio of 26.80. The price-to-sales ratio is 2.60, and the price-to-book ratio stands at 39.17.
| PE Ratio | 26.80 |
| PS Ratio | 2.60 |
| PB Ratio | 39.17 |
| P/TBV Ratio | 13.39 |
| P/FCF Ratio | 10.28 |
| P/OCF Ratio | 14.29 |
On an enterprise value basis, Amrize Ltd trades at an EV/EBITDA multiple of 13.40 and an EV/FCF ratio of 11.22. The EV/Sales ratio of 3.10 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 20.08 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.10 |
| EV / EBITDA | 13.40 |
| EV / EBIT | 20.08 |
| EV / FCF | 11.22 |
Amrize Ltd maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 54.23, indicating elevated leverage, while an interest coverage ratio of 7.56 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.40 |
| Quick Ratio | 0.80 |
| Debt / Equity | 54.23 |
| Debt / EBITDA | 2.57 |
| Interest Coverage | 7.56 |
Amrize Ltd posts a return on equity of 290.09 and a return on invested capital of 7.31.
| Return on Equity (ROE) | 290.09 |
| Return on Assets (ROA) | 4.96 |
| Return on Invested Capital (ROIC) | 7.31 |
| Return on Capital Employed (ROCE) | 20.82 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.61 |
Over the trailing twelve months, Amrize Ltd has paid 345.00M in income taxes, reflecting an effective tax rate of 23.23.
| Income Tax | 345.00M |
| Effective Tax Rate | 23.23 |
Amrize Ltd's stock has gained approximately 3.57761% over the past 52 weeks. The 50-day moving average sits at 54.47, while the 200-day moving average is 53.77.
| Beta (5Y) | N/A |
| 52-Week Price Change | 3.57761% |
| 50-Day Moving Average | 54.47 |
| 200-Day Moving Average | 53.77 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Amrize Ltd generated 11.91B in revenue and converted that into 1.16B in net income, yielding earnings per share of 2.08. EBITDA reached 2.76B, while operating income came in at 1.84B.
| Revenue | 11.91B |
| Gross Profit | 3.02B |
| Operating Income | 1.84B |
| Pretax Income | 1.49B |
| Net Income | 1.16B |
| EBITDA | 2.76B |
| EBIT | 1.84B |
| Earnings Per Share (EPS) | 2.08 |
Amrize Ltd holds 1.10B in cash and equivalents against 7.10B in total debt, resulting in a net debt position of 4.95B. Total book value stands at 791.00M, with working capital of 1.23B providing operational flexibility.
| Cash & Cash Equivalents | 1.10B |
| Total Debt | 7.10B |
| Net Debt | 4.95B |
| Equity (Book Value) | 791.00M |
| Book Value Per Share | 1.43 |
| Working Capital | 1.23B |
Amrize Ltd produced 2.17B in operating cash flow over the past twelve months. After subtracting -849.00M in capital expenditures, free cash flow totaled 1.32B - equivalent to 2.38 per share.
| Operating Cash Flow | 2.17B |
| Capital Expenditures | -849.00M |
| Free Cash Flow | 1.32B |
| FCF Per Share | 2.38 |
Amrize Ltd operates with a gross margin of 25.38, reflecting its pricing power and cost economics. The operating margin of 15.46 and net profit margin of 9.70 provide insight into operational efficiency.
| Gross Margin | 25.38 |
| Operating Margin | 15.46 |
| Pretax Margin | 12.47 |
| Profit Margin | 9.70 |
| EBITDA Margin | 23.17 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 2.31 |
| FCF Yield | 9.73 |
Amrize Ltd posts an Altman Z-Score of 3.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.19 |